Results 91 to 100 of about 4,224,645 (261)

Antibiotic prescription rate for upper respiratory tract infections and risks for unnecessary prescription in Croatia [Stopa propisivanja antibiotika za infekcije gornjeg dišnog trakta i rizici za nepotrebno propisivanje antibiotika u Hrvatskoj] [PDF]

, 2013
Overprescribing of antibiotics in primary care has been recognized as public health problem. We investigated visits prescription rate of antibiotics to patients with upper respiratory tract infections (URTI) and unnecessary prescription for ...
Kern, Josipa, Botica, Iva, Stamenić, Valerija, Stojanović Špehar, Stanislava, Tambić Andrašević, Arjana, Vrca Botica, Marija   +5 more
core   +1 more source

POTENTIALS OF SYMPTOMATIC TREATMENT OF ACUTE RESPIRATORY TRACT INFECTIONS IN CHILDREN

Вопросы современной педиатрии, 2013
Acute infection of upper respiratory tract is one of the most topical medical and social problems: it is respiratory diseases that cause the majority of children’s and adults’ non-attendance of school lessons and working days.
L. R. Selimzyanova, E. A. Promyslova, E. А. Vishneva   +2 more
doaj   +1 more source

An investigation of the association between herpesviruses and respiratory disease in racehorses in Western Australia [PDF]

, 2003
Respiratory disease is an important cause of wastage in the Australian horse racing industry and viruses are frequently suspected as aetiological agents of respiratory disease or poor performance by clinicians and trainers but confirmation is seldom ...
Wang, Liping
core  

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, the Paediatric Rheumatology International Trials Organisation (PRINTO); the Pediatric Rheumatology Collaborative Study Group (PRCSG), Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Alberto Martini, Daniel L. Lovell, Nicolino Ruperto   +52 more
wiley   +1 more source

Airway Microbiome Is Associated with Atherosclerosis in Adults from Southern Caribbean

Microorganisms
Subclinical atherosclerosis (SCA) has been associated with lung function in many populations. Accordingly, those factors involved in respiratory health may contribute to the mechanisms linking pulmonary and cardiovascular disorders.
Diana Mena-Yi, Alejandra Puerto, Sara Mestra, Josefina Zakzuk, Marlon Munera, Fernando Manzur-Jattin, Maria S. Ruiz-Diaz, Gustavo Mora-Garcia   +7 more
doaj   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Outcomes of Tapering Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial

Arthritis &Rheumatology, EarlyView.
Objective Evidence supporting tapering of biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA) remains limited. We evaluated the efficacy and safety of a structured b/tsDMARD‐tapering strategy in patients with RA who had achieved sustained ...
Dong‐Jin Park, Sung‐Eun Choi, Ji‐Hyoun Kang, Jung‐Yoon Choe, Hye‐Soon Lee, So‐Young Bang, Yun‐Hong Cheon, Sang‐Il Lee, Mingyo Kim, Yoon‐Kyoung Sung, Soo‐Kyung Cho, Jae Hyun Jung, Sung Hae Chang, Sung Won Lee, Yeon‐Ah Lee, Seung‐Geun Lee, Hyun‐Sook Kim, Seung‐Ki Kwok, Seung‐Cheol Shim, Shin‐Seok Lee   +19 more
wiley   +1 more source

Upper respiratory tract symptoms and fever in the 144 neutropenic patients where NPA were obtained.

, 2013
NOTE. URTS, upper respiratory tract symptoms; OR, odds ratio; RSV, respiratory syncytial virus.aOne case of co-infection of HRV and AdV.bThis patient did not have URTS either.
Kristina Broliden (60331), Oscar Norbeck (60328), Per Ljungman (323971), Thomas Tolfvenstam (60332), Michelle Wong (231504), Lars Öhrmalm (305544), Carl Aust (323970)   +6 more
core   +1 more source

Incidence and risk factors for respiratory syncytial virus and human metapneumovirus infections among children in the remote highlands of Peru [PDF]

, 2015
The disease burden and risk factors for respiratory syncytial virus (RSV) and human metapneumovirus (MPV) infections among children living in remote, rural areas remain unclear.; We conducted a prospective, household-based cohort study of children aged ...
Gil, Ana I., Philip J Budge, Kathryn M. Edwards (534416), Verastegui, Hector, Yuwei Zhu, Hector Verastegui, Grijalva, Carlos G, Carlos G. Grijalva, Grijalva, Carlos G., Stella Hartinger, Stella Hartinger (759804), Gil, Ana I, Marie R Griffin, Griffin, Marie R., Wu, Andrew, Lanata, Claudio F., Marie R. Griffin (209725), Marie R. Griffin, Monika Johnson, Ana I. Gil, Philip J. Budge (389401), Williams, John, Andrew Wu, Carlos G. Grijalva (236548), John Williams (32544), Zhu, Yuwei, Claudio F Lanata, Hector Verastegui (534417), Kathryn M Edwards, Andrew Wu (90389), Edwards, Kathryn M, John Williams, Yuwei Zhu (236550), Budge, Philip J, Johnson, Monika, Hartinger, Stella, Ana I. Gil (534420), Lanata, Claudio F, Ana I Gil, Claudio F. Lanata, Edwards, Kathryn M., Philip J. Budge, Griffin, Marie R, Carlos G Grijalva, Andrew Wu, Kathryn M. Edwards, Claudio F. Lanata (454212), Monika Johnson (12861), Budge, Philip J., Griffin Marie R., Grijalva Carlos G., Johnson Monika, Hartinger Stella, Lanata Claudio F., Zhu Yuwei, Verastegui Hector, Budge Philip J., Williams John, Wu Andrew, Edwards Kathryn M., Gil Ana I.   +60 more
core   +2 more sources

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source